Literature DB >> 32147954

Pleuroparenchymal fibroelastosis in patients with idiopathic pulmonary fibrosis.

Song-I Lee1,2, Eun Jin Chae3, Joon Seon Song4, Jae Ha Lee5, Jin Woo Song1.   

Abstract

BACKGROUND AND
OBJECTIVE: PPFE is characterized by fibrosis in the pleura and subpleural lung parenchyma in the upper lobes, while other types of ILD, mainly UIP, can be observed in about half of the patients in their lower lobes. The aim of this study was to evaluate the clinical significance of the radiologically defined PPFE in patients with IPF.
METHODS: Clinical data and chest CT images were retrospectively analysed in 445 patients with IPF (biopsy-proven cases, n = 165). The radiological criteria of PPFE were defined as follows: (i) bilateral subpleural dense fibrosis with or without pleural thickening in the upper lobes, (ii) evidence of disease progression and (iii) no clinical evidence of identifiable aetiologies.
RESULTS: The median follow-up period was 43.0 months. The mean age of the patients was 66.4 years and 76.4% were male. PPFE was identified in 28 patients (6.3%). The PPFE group showed lower BMI and lung function (FVC and TLC) at baseline, more frequent pneumothorax and pneumomediastinum, higher decline rates in lung function and poorer prognosis during follow-up than the no-PPFE group. PPFE was an independent risk factor (HR = 2.953, 95% CI: 1.350-6.460, P = 0.007) for pneumothorax or pneumomediastinum, but not for mortality in patients with IPF.
CONCLUSION: Among patients with IPF, the PPFE group, when compared to the no-PPFE group, showed lower BMI and lung function and showed more frequent complications and poorer survival during follow-up.
© 2020 Asian Pacific Society of Respirology.

Entities:  

Keywords:  fibroelastosis; idiopathic pulmonary fibrosis; interstitial lung disease; prognosis; radiological diagnostic

Mesh:

Year:  2020        PMID: 32147954     DOI: 10.1111/resp.13796

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

1.  Clinics in diagnostic imaging (212). Pleuroparenchymal fibroelastosis (PPFE).

Authors:  Glenn Khai Wern Yong; Kenneth Eng Ling Kwan; Khoon Leong Chuah; Gin Tsen Chai
Journal:  Singapore Med J       Date:  2022-02       Impact factor: 3.331

2.  Pleuroparenchymal Fibroelastosis: A Case Report.

Authors:  Oumayma Haloui; Fatima El Allam; Ouiame Nabou; Afaf Thouil; Hatim Kouismi
Journal:  Cureus       Date:  2022-09-15

3.  Pleuroparenchymal fibroelastosis in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Jieun Kang; Woo Jung Seo; Eun Young Lee; Sung Hae Chang; Jooae Choe; Seokchan Hong; Jin Woo Song
Journal:  Respir Res       Date:  2022-06-02

4.  Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia.

Authors:  Keishi Sugino; Hirotaka Ono; Hiroshige Shimizu; Takeyuki Kurosawa; Keiko Matsumoto; Masahiro Ando; Kiyoshi Mori; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  ERJ Open Res       Date:  2021-03-01

5.  Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias.

Authors:  Tomoyuki Fujisawa; Yasuoki Horiike; Ryoko Egashira; Hiromitsu Sumikawa; Tae Iwasawa; Shoichiro Matsushita; Hiroaki Sugiura; Kensuke Kataoka; Mikiko Hashisako; Hideki Yasui; Hironao Hozumi; Masato Karayama; Yuzo Suzuki; Kazuki Furuhashi; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Takafumi Suda
Journal:  Respir Res       Date:  2021-11-11

6.  Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment.

Authors:  Eyjolfur Gudmundsson; An Zhao; Nesrin Mogulkoc; Iain Stewart; Mark G Jones; Coline H M Van Moorsel; Recep Savas; Christopher J Brereton; Hendrik W Van Es; Omer Unat; Katarina Pontoppidan; Frouke Van Beek; Marcel Veltkamp; Bahareh Gholipour; Arjun Nair; Athol U Wells; Sam M Janes; Daniel C Alexander; Joseph Jacob
Journal:  EClinicalMedicine       Date:  2021-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.